ABL proto-oncogene 1, non-receptor tyrosine kinase. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Regorafenib CHEMBL1946170 |
Tyrosine-protein kinase ABL inhibitor Inhibitor Small molecule |
ChEMBL only | 43 |
| Imatinib CHEMBL941 |
Tyrosine-protein kinase ABL inhibitor Inhibitor Bcr/Abl fusion protein inhibitor Inhibitor Small molecule |
✓ Both | 33 |
| Dasatinib CHEMBL5416410 |
Bcr/Abl fusion protein inhibitor Inhibitor Small molecule |
✓ Both | 29 |
| Olverembatinib CHEMBL2316582 |
Bcr/Abl fusion protein inhibitor Inhibitor Small molecule |
✓ Both | 16 |
| Nilotinib CHEMBL255863 |
Tyrosine-protein kinase ABL inhibitor Inhibitor Bcr/Abl fusion protein inhibitor Inhibitor Small molecule |
✓ Both | 12 |
| Ponatinib CHEMBL1171837 |
Bcr/Abl fusion protein inhibitor Inhibitor Small molecule |
✓ Both | 12 |
| Asciminib CHEMBL4208229 |
Tyrosine-protein kinase ABL inhibitor Inhibitor Bcr/Abl fusion protein inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Bosutinib CHEMBL288441 |
Tyrosine-protein kinase ABL inhibitor Inhibitor Bcr/Abl fusion protein inhibitor Inhibitor Small molecule |
✓ Both | 6 |
| Radotinib HCl CHEMBL4297524 |
Bcr/Abl fusion protein inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Acute myeloid leukemia | 6 | Phase 2 |
| Acute lymphoblastic leukemia | 5 | Phase 3 |
| Gastrointestinal stromal tumor | 4 | Phase 3 |
| T-cell acute lymphoblastic leukemia | 3 | Phase 3 |
| Chronic myeloid leukemia | 3 | Phase 3 |
| Glioblastoma | 3 | Phase 2/3 |
| Breast cancer | 3 | Phase 2 |
| Leukemia | 3 | Phase 2 |
| Alzheimer disease | 2 | Phase 3 |
| COVID-19 | 2 | Phase 3 |
| Childhood leukemia | 2 | Phase 3 |
| Chronic graft versus host disease | 2 | Phase 3 |
| Ewing sarcoma | 2 | Phase 2/3 |
| Precursor B-cell acute lymphoblastic leukemia | 2 | Phase 2/3 |
| Lewy body dementia | 2 | Phase 2 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
